{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:40:19Z","timestamp":1788993619249,"version":"build-2803163510"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cytogfr.2025.10.005","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:21:08Z","timestamp":1761265268000},"page":"149-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Role of cytokine-based immunotherapy approaches in gastrointestinal cancers"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-7115","authenticated-orcid":false,"given":"Rafik","family":"ElBeblawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midhun","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.cytogfr.2025.10.005_bib1","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/CM9.0000000000003225","article-title":"Burden of six major types of digestive system cancers globally and in China","volume":"137","author":"Zhou","year":"2024","journal-title":"Chin. Med J. (Engl. )"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer Journal Clinicians"},{"key":"10.1016\/j.cytogfr.2025.10.005_bib3","unstructured":"N.C. Institute, Cancer Stat Facts: Colorectal Cancer, 2025. \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html\u3009. 2025)."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib4","doi-asserted-by":"crossref","first-page":"1466159","DOI":"10.3389\/fonc.2024.1466159","article-title":"Global, regional, and national trends in colorectal cancer burden from 1990 to 2021 and projections to 2040","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib5","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib6","doi-asserted-by":"crossref","first-page":"1485303","DOI":"10.3389\/fimmu.2024.1485303","article-title":"Efficacy and safety of PD-1\/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.005_bib7","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.3390\/curroncol30110711","article-title":"Advances in immunotherapy for hepatocellular carcinoma (HCC)","volume":"30","author":"Bicer","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241273286","article-title":"Immune checkpoint inhibitor plus chemotherapy as First-Line treatment for advanced gastric or gastroesophageal junction cancer: a systematic review and Meta-Analysis","volume":"23","author":"Zhang","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.005_bib9","article-title":"Immunotherapy in gastroesophageal adenocarcinoma: what is the state of management?","volume":"1","author":"Bever","year":"2024","journal-title":"Surg. Oncol. Insight"},{"key":"10.1016\/j.cytogfr.2025.10.005_bib10","doi-asserted-by":"crossref","first-page":"1344272","DOI":"10.3389\/fimmu.2024.1344272","article-title":"Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12032-025-02724-2","article-title":"Promising immunotherapeutic treatments for colon cancer","volume":"42","author":"Gutiu","year":"2025","journal-title":"Med Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib12","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2147\/DDDT.S308578","article-title":"Clinical application of cytokines in cancer immunotherapy","volume":"15","author":"Qiu","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4062\/biomolther.2023.196","article-title":"Current development status of cytokines for cancer immunotherapy","volume":"32","author":"Song","year":"2024","journal-title":"Biomol. Ther. (Seoul. )"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.005_bib14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/cac2.12295","article-title":"Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy","volume":"42","author":"Bhat","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.cytogfr.2025.10.005_bib15","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.12659\/MSM.907439","article-title":"Targeting Interleukin-6 (IL-6) sensitizes Anti-PD-L1 treatment in a colorectal cancer preclinical model","volume":"24","author":"Li","year":"2018","journal-title":"Med Sci. Monit."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.005_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155006","article-title":"Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a t cell- and CXCR3-dependent manner","volume":"8","author":"Ware","year":"2023","journal-title":"JCI Insight"},{"issue":"13","key":"10.1016\/j.cytogfr.2025.10.005_bib17","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-23-3567","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity from a phase I study of simlukafusp alfa (FAP-IL2v) in advanced\/metastatic solid tumors","volume":"30","author":"Steeghs","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.005_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010143","article-title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","volume":"12","author":"Vaishampayan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cytogfr.2025.10.005_bib19","unstructured":"Medicenna, Medicenna Presents Compelling Results on Ability\u20111 Clinical Trial, 2025."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib20","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.4251\/wjgo.v16.i5.1676","article-title":"Interleukin-1\u03b2: friend or foe for gastrointestinal cancers","volume":"16","author":"Khawkhiaw","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib21","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers12071791","article-title":"Interleukin-1\u03b2 and cancer","volume":"12","author":"R\u00e9b\u00e9","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1074-7613(00)80402-1","article-title":"MyD88: an adapter that recruits IRAK to the IL-1 receptor complex","volume":"7","author":"Wesche","year":"1997","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.10.005_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1474319","article-title":"Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study","volume":"7","author":"Isambert","year":"2018","journal-title":"Oncoimmunology"},{"issue":"4_","key":"10.1016\/j.cytogfr.2025.10.005_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.2018.36.4_suppl.449","article-title":"Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with localized pancreatic ductal adenocarcinoma (PDAC)","volume":"36","author":"Becerra","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"22_ement","key":"10.1016\/j.cytogfr.2025.10.005_bib25","doi-asserted-by":"crossref","first-page":"PR005","DOI":"10.1158\/1538-7445.PANCA22-PR005","article-title":"Abstract PR005: primary results of PanCAN-SR1, a phase 1b study evaluating gemcitabine, nab-Paclitaxel, canakinumab, and spartalizumab to target IL-1\u03b2 and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis","volume":"82","author":"Oberstein","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib26","doi-asserted-by":"crossref","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cytogfr.2025.01.001","article-title":"Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy","volume":"85","author":"Wu","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"issue":"18","key":"10.1016\/j.cytogfr.2025.10.005_bib29","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1200\/JCO.23.01965","article-title":"Randomized phase II study of Nab-Paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer: survival and cachexia","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"180","author":"Chen","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"27","key":"10.1016\/j.cytogfr.2025.10.005_bib31","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7_ement","key":"10.1016\/j.cytogfr.2025.10.005_bib32","doi-asserted-by":"crossref","first-page":"CT136","DOI":"10.1158\/1538-7445.AM2024-CT136","article-title":"Abstract CT136: phase ib study of siltuximab and spartalizumab in advanced pancreatic cancer","volume":"84","author":"Alese","year":"2024","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib33","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1073\/pnas.1820459116","article-title":"Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma","volume":"116","author":"Ebbing","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12672-024-01011-2","article-title":"Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity","volume":"15","author":"Xu","year":"2024","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib36","doi-asserted-by":"crossref","first-page":"1360063","DOI":"10.3389\/fimmu.2024.1360063","article-title":"Riboswitch-controlled IL-12 gene therapy reduces hepatocellular cancer in mice","volume":"15","author":"D\u00fcchs","year":"2024","journal-title":"Front Immunol."},{"issue":"15","key":"10.1016\/j.cytogfr.2025.10.005_bib37","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1158\/1078-0432.CCR-04-0265","article-title":"A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients","volume":"10","author":"Parihar","year":"2004","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.005_bib38","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","article-title":"Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer","volume":"20","author":"Barton","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/biomedicines12051065","article-title":"Long-term follow-up of phase I trial of oncolytic adenovirus-mediated cytotoxic and Interleukin-12 gene therapy for treatment of metastatic pancreatic cancer","volume":"12","author":"Bhatnagar","year":"2024","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005813","article-title":"First-in-human phase ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma","volume":"11","author":"Strauss","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","article-title":"First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib43","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.21037\/jgo-24-71","article-title":"Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: a phase II trial protocol","volume":"15","author":"Victory","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"issue":"8062","key":"10.1016\/j.cytogfr.2025.10.005_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2025.10.005_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978195","article-title":"CAR T-cells for colorectal cancer immunotherapy: ready to go?","volume":"13","author":"Ghazi","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib46","doi-asserted-by":"crossref","first-page":"1184703","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Pharm."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib47","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1007\/s10637-021-01160-z","article-title":"IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer","volume":"39","author":"Hu","year":"2021","journal-title":"Invest N. Drugs"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib48","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4049\/jimmunol.1600019","article-title":"IL-15 Trans-Signaling with the superagonist RLI promotes Effector\/Memory CD8+ t cell responses and enhances antitumor activity of PD-1 antagonists","volume":"197","author":"Desbois","year":"2016","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib49","article-title":"957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study","volume":"9","author":"Altan","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 t cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.cytogfr.2025.10.005_bib51","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-Cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.10.005_bib52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nri1688","article-title":"Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation","volume":"5","author":"Leonard","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib53","doi-asserted-by":"crossref","first-page":"1369743","DOI":"10.3389\/fimmu.2024.1369743","article-title":"Therapeutic potential of interleukin-21 in cancer","volume":"15","author":"Isvoranu","year":"2024","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2011.599","article-title":"A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer","volume":"106","author":"Steele","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cytogfr.2025.10.005_bib55","doi-asserted-by":"crossref","first-page":"1345473","DOI":"10.3389\/fimmu.2024.1345473","article-title":"Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1\/IL-21 mutein fusion protein","volume":"15","author":"Kroenke","year":"2024","journal-title":"Front Immunol."},{"issue":"13_ement","key":"10.1016\/j.cytogfr.2025.10.005_bib56","doi-asserted-by":"crossref","first-page":"CT205","DOI":"10.1158\/1538-7445.AM2021-CT205","article-title":"Abstract CT205: design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors","volume":"81","author":"Durm","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib57","doi-asserted-by":"crossref","first-page":"1506632","DOI":"10.3389\/fimmu.2024.1506632","article-title":"GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer","volume":"15","author":"Xuan","year":"2024","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-specific CAR t cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.005_bib59","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.3390\/ijms20081887","article-title":"Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases","volume":"20","author":"Ruder","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib60","article-title":"TNF-\u03b1, and TNFRs in gastrointestinal cancers","volume":"263","author":"Mozooni","year":"2024","journal-title":"Pathol. Res Pr."},{"issue":"23","key":"10.1016\/j.cytogfr.2025.10.005_bib61","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib62","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","article-title":"A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer","volume":"19","author":"Brown","year":"2008","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib63","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.gie.2012.01.042","article-title":"Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer","volume":"75","author":"Chang","year":"2012","journal-title":"Gastrointest. Endosc."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib64","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.gie.2011.10.007","article-title":"EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I\/II study","volume":"75","author":"Hecht","year":"2012","journal-title":"Gastrointest. Endosc."},{"issue":"5-6","key":"10.1016\/j.cytogfr.2025.10.005_bib65","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000323488","article-title":"A pilot feasibility study of TNFerade\u2122 biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer","volume":"79","author":"Citrin","year":"2010","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib66","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1200\/JCO.2012.44.7516","article-title":"Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results","volume":"31","author":"Herman","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.cytogfr.2025.10.005_bib67","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.ejca.2010.07.012","article-title":"Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy","volume":"46","author":"Santoro","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib68","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bjc.6605858","article-title":"Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma","volume":"103","author":"Santoro","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.005_bib69","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdq436","article-title":"Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies","volume":"22","author":"Mammoliti","year":"2011","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1067\/msy.2001.110365","article-title":"Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer","volume":"129","author":"Bartlett","year":"2001","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Vara","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib72","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.10.005_bib73","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.3390\/ijms22094871","article-title":"Vascular endothelial growth factor, a key modulator of the Anti-Tumor immune response","volume":"22","author":"Geindreau","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib74","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","article-title":"Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa b activation in hemopoietic progenitor cells","volume":"160","author":"Oyama","year":"1998","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ t cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib76","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib77","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib78","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib79","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib80","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/nrd1727","article-title":"Bevacizumab","author":"Ellis","year":"2005","journal-title":"Nat. Rev. Drug Discov. Suppl."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib81","first-page":"S62","article-title":"Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer","volume":"4","author":"Hurwitz","year":"2004","journal-title":"Clin. Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib82","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1634\/theoncologist.12-3-356","article-title":"FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"issue":"28","key":"10.1016\/j.cytogfr.2025.10.005_bib83","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib84","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol."},{"issue":"9911","key":"10.1016\/j.cytogfr.2025.10.005_bib85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.005_bib86","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.cytogfr.2025.10.005_bib87","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib88","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"20","key":"10.1016\/j.cytogfr.2025.10.005_bib89","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.005_bib90","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib91","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib92","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.cytogfr.2025.10.005_bib93","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group b (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib94","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.24.00337","article-title":"Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: clinical and biomarker data from the randomized phase II IMbrave151 trial","volume":"43","author":"Macarulla","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.64","article-title":"Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types","volume":"48","author":"Hong","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a Double-Edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol."},{"issue":"19","key":"10.1016\/j.cytogfr.2025.10.005_bib97","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-Transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"19","key":"10.1016\/j.cytogfr.2025.10.005_bib98","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med"},{"issue":"15_","key":"10.1016\/j.cytogfr.2025.10.005_bib99","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2021.39.15_suppl.4134","article-title":"A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC)","volume":"39","author":"Lee","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.cytogfr.2025.10.005_bib100","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-24-3403","article-title":"A phase II study of neoadjuvant GVAX and cyclophosphamide combined with nivolumab and SBRT followed by surgery in borderline resectable pancreatic adenocarcinoma","volume":"31","author":"Agarwal","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib101","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","article-title":"TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial","volume":"122","author":"Palmer","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib102","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study","volume":"32","author":"Valle","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952066","article-title":"PD-1 inhibitor combined with radiotherapy and GM-CSF (PRaG) in patients with metastatic solid tumors: an open-label phase II study","volume":"13","author":"Kong","year":"2022","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.005_bib104","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cam4.2763","article-title":"A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer","volume":"9","author":"Yarchoan","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.cytogfr.2025.10.005_bib105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2407-10-209","article-title":"A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma","volume":"10","author":"Greten","year":"2010","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib106","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000533650","article-title":"PHOCUS: a phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma","volume":"13","author":"Abou-Alfa","year":"2024","journal-title":"Liver Cancer"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.005_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081600","article-title":"Signaling by type I interferons in immune cells: disease consequences","volume":"16","author":"Zannikou","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib108","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111647","article-title":"Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8(+) t cell exhaustion and curtails anti-PD-1 efficacy","volume":"41","author":"Chen","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.510310111","article-title":"Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma","volume":"31","author":"Llovet","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib111","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e3182363ff9","article-title":"Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection","volume":"255","author":"Chen","year":"2012","journal-title":"Ann. Surg."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/JHC.S215235","article-title":"Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma","volume":"6","author":"Zakka","year":"2019","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12957-016-0903-8","article-title":"Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments","volume":"14","author":"Kassahun","year":"2016","journal-title":"World J. Surg. Oncol."},{"issue":"7-8","key":"10.1016\/j.cytogfr.2025.10.005_bib114","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000524872","article-title":"Successful liver transplantation of recurrent fibrolamellar carcinoma following clinical and pathologic complete response to triple immunochemotherapy: a case report","volume":"45","author":"Kang","year":"2022","journal-title":"Oncol. Res Treat."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.005_bib115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000513358","article-title":"Early experiences with triple immunochemotherapy in adolescents and young adults with High-Risk fibrolamellar carcinoma","volume":"99","author":"Gottlieb","year":"2021","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.005_bib116","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"K\u00f6lby","year":"2003","journal-title":"Br. J. Surg."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib117","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2407-5-37","article-title":"Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma \u2013 CapRI: study protocol [ISRCTN62866759","volume":"5","author":"Knaebel","year":"2005","journal-title":"BMC Cancer"},{"issue":"33","key":"10.1016\/j.cytogfr.2025.10.005_bib118","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2011.38.2960","article-title":"Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma","volume":"30","author":"Schmidt","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib119","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/SLA.0000000000001190","article-title":"Interferon-based adjuvant chemoradiation for resected pancreatic head cancer: Long-term follow-up of the Virginia mason protocol","volume":"263","author":"Rocha","year":"2016","journal-title":"Ann. Surg."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.10.005_bib120","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.1996.14.10.2674","article-title":"Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer","volume":"14","author":"Greco","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.005_bib121","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.1996.14.8.2280","article-title":"Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal cancer working party of the United Kingdom medical research council","volume":"14","author":"Seymour","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.005_bib122","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.005_bib123","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth Factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.005_bib124","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2023.05.038","article-title":"Transforming growth Factor-\u03b2 blockade in pancreatic cancer enhances sensitivity to combination chemotherapy","volume":"165","author":"Qiang","year":"2023","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.10.005_bib125","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. Gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib126","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002068","article-title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","volume":"9","author":"Melisi","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"24","key":"10.1016\/j.cytogfr.2025.10.005_bib127","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1158\/1078-0432.CCR-21-1504","article-title":"First-In-Human phase I study of a Next-Generation, oral, TGF\u03b2 receptor 1 inhibitor, LY3200882, in patients with advanced cancer","volume":"27","author":"Yap","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.10.005_bib128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.cytogfr.2025.10.005_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133248","article-title":"The TGF-\u03b2 pathway: a pharmacological target in hepatocellular carcinoma?","volume":"13","author":"Gonzalez-Sanchez","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.005_bib130","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000056","article-title":"A phase 2 study of galunisertib (TGF-\u03b21 Receptor Type I Inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma","volume":"10","author":"Kelley","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.cytogfr.2025.10.005_bib131","doi-asserted-by":"crossref","first-page":"1376551","DOI":"10.3389\/fonc.2024.1376551","article-title":"First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-\u00df1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors","volume":"14","author":"Shimizu","year":"2024","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.005_bib132","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/HEP.0000000000000965","article-title":"Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: a randomized phase 2\/3 trial","volume":"81","author":"Oh","year":"2025","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.005_bib133","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20511","article-title":"Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells","volume":"47","author":"Biswas","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.005_bib134","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.humpath.2006.10.005","article-title":"TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer","volume":"38","author":"Ogino","year":"2007","journal-title":"Hum. Pathol."},{"issue":"3_","key":"10.1016\/j.cytogfr.2025.10.005_bib135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JCO.2021.39.3_suppl.79","article-title":"Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy","volume":"39","author":"Morris","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.cytogfr.2025.10.005_bib136","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.3390\/ijms25137400","article-title":"TGF-\u03b2 modulated pathways in colorectal cancer: new potential therapeutic opportunities","volume":"25","author":"Fasano","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"16_","key":"10.1016\/j.cytogfr.2025.10.005_bib137","article-title":"Oncolytic virus VG161 in combination with camrelizumab as second-line therapy in patients with advanced primary hepatocellular carcinoma: a phase Ib\/IIa clinical study","volume":"43","author":"Shen","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:20:12Z","timestamp":1781234412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":137,"alternative-id":["S1359610125001406"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.10.005","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of cytokine-based immunotherapy approaches in gastrointestinal cancers","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}